Cutia Therapeutics (HK:2487) has released an update.
Cutia Therapeutics has reported a remarkable revenue surge of approximately 129.9% for the first nine months of 2024, reaching RMB148.9 million. This growth highlights the strong market performance of its commercialized products, signaling potential opportunities for investors. However, the company advises caution as these figures are based on preliminary unaudited data.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.